Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Short Interest Down 16.9% in February

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) saw a large decrease in short interest during the month of February. As of February 27th, there was short interest totaling 82,219 shares, a decrease of 16.9% from the February 12th total of 98,894 shares. Currently, 1.2% of the company’s stock are short sold. Based on an average daily trading volume, of 25,376 shares, the short-interest ratio is currently 3.2 days. Based on an average daily trading volume, of 25,376 shares, the short-interest ratio is currently 3.2 days. Currently, 1.2% of the company’s stock are short sold.

Lixte Biotechnology Stock Performance

Shares of LIXT stock traded down $0.04 during mid-day trading on Monday, reaching $3.07. 11,054 shares of the company were exchanged, compared to its average volume of 70,683. Lixte Biotechnology has a fifty-two week low of $0.64 and a fifty-two week high of $6.26. The company has a market capitalization of $22.96 million, a P/E ratio of -2.60 and a beta of 0.86. The business’s 50 day simple moving average is $3.19 and its 200 day simple moving average is $4.03.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in LIXT. Axxcess Wealth Management LLC bought a new stake in shares of Lixte Biotechnology in the 4th quarter worth about $54,000. XTX Topco Ltd acquired a new stake in shares of Lixte Biotechnology in the 4th quarter valued at about $57,000. Geode Capital Management LLC lifted its position in shares of Lixte Biotechnology by 25.9% during the fourth quarter. Geode Capital Management LLC now owns 52,163 shares of the company’s stock worth $205,000 after purchasing an additional 10,722 shares during the last quarter. DRW Securities LLC grew its stake in Lixte Biotechnology by 11.6% in the fourth quarter. DRW Securities LLC now owns 54,126 shares of the company’s stock worth $213,000 after purchasing an additional 5,645 shares in the last quarter. Finally, Federation des caisses Desjardins du Quebec grew its stake in Lixte Biotechnology by 83.6% in the fourth quarter. Federation des caisses Desjardins du Quebec now owns 93,380 shares of the company’s stock worth $367,000 after purchasing an additional 42,530 shares in the last quarter. 5.10% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Lixte Biotechnology in a research report on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has an average rating of “Sell”.

Lixte Biotechnology Company Profile

Lixte Biotechnology Holdings, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for the treatment of cancer. The company’s research centers on selectively targeting key enzymes and pathways involved in DNA damage response and cell cycle regulation, with the goal of creating novel oncology drugs that improve patient outcomes with manageable safety profiles.

Lixte’s lead programs include selective inhibitors of cell cycle checkpoints and related targets, designed to potentiate the effects of standard-of-care chemotherapies and overcome resistance mechanisms.